DealShare CEO Quits Amid Truemeds Deal Talks

Key Takeaways

• CEO exit: Kamaldeep Singh has stepped down as DealShare CEO and is moving to Indofast Energy as its chief executive.
• Acquisition discussions: DealShare has reportedly held advanced discussions with Truemeds over a potential share-swap transaction.
• Sharp valuation decline: The proposed transaction has reportedly valued DealShare at just over $90 million, compared with its peak valuation of approximately $1.7 billion in 2022.
• Business restructuring: DealShare has scaled back its online operations and shifted its focus towards physical retail stores.
• Leadership uncertainty: The company has not publicly established a confirmed successor to Singh in the reporting available on October 13, 2026.
• Deal remains uncertain: Truemeds’ existing investors have reportedly raised concerns about the proposed transaction, and DealShare has also explored other potential buyers.

DealShare CEO Kamaldeep Singh Steps Down

Kamaldeep Singh’s departure marks another leadership change at DealShare as the e-commerce company attempts to determine a sustainable future for its business.

Singh joined DealShare in December 2022 as president of its retail business and became CEO in January 2024. His appointment followed a period of restructuring and founder departures as the company reconsidered its business model and sought a path towards profitability.

Before joining DealShare, Singh spent nearly 15 years at Big Bazaar, where he held senior leadership responsibilities and served as chief executive for more than a year. His experience in organised retail was relevant to DealShare’s effort to combine online commerce with physical stores.

According to Inc42’s October 13 report, Singh has moved to Indofast Energy as CEO. The company operates in the electric mobility sector, focusing on battery swapping and battery-as-a-service solutions. Singh did not publicly specify that his departure was caused by the reported acquisition negotiations.

The timing is significant because DealShare is navigating multiple challenges at once: a reduced online business, questions over its future operating model, investor discussions about ownership and further management changes.

The departure does not, by itself, confirm that a sale is imminent. However, it adds to the uncertainty surrounding the company while potential buyers and investors evaluate its remaining business and financial position.

Why Is DealShare in Acquisition Talks With Truemeds?

DealShare has reportedly been in advanced discussions with Truemeds, an online pharmacy platform, over a possible acquisition through a share-swap transaction.

Under a share-swap structure, the parties use shares rather than relying entirely on a cash payment. The exact mechanics depend on the final agreement, including how the companies are valued, which securities are exchanged and how existing shareholders are treated.

Reports published in August 2026 said the potential transaction could value DealShare at slightly more than $90 million. That figure is a reported potential valuation, not a confirmed sale price or evidence that a definitive agreement has been signed.

WestBridge Capital is a notable factor in the discussions because it is an investor in both companies. A common investor can help facilitate conversations between businesses, but it does not guarantee that every shareholder will support the transaction.

Truemeds’ existing investors have reportedly not been fully aligned with the proposed deal. DealShare has also been reported to be in discussions with other potential buyers, meaning Truemeds is not necessarily the only possible outcome.

As of October 13, 2026, the available reporting does not establish that the acquisition has closed. Any assessment of the transaction should therefore distinguish between reported negotiations and a completed deal.

DealShare’s Valuation Has Fallen From $1.7 Billion

DealShare’s reported acquisition discussions highlight the dramatic change in its valuation since it reached unicorn status.

The company was valued at approximately $1.7 billion in 2022 after raising capital from investors including Tiger Global and Alpha Wave Global. It had built a business around selling groceries and household essentials online, particularly to value-conscious consumers in smaller Indian cities.

The reported potential valuation of just over $90 million represents a decline of roughly 95% from its peak.

Valuation indicator	Reported figure
Peak valuation in 2022	Approximately $1.7 billion
Potential valuation in reported Truemeds discussions	Just over $90 million
Approximate decline from peak	Around 95%
Funding raised over time	Nearly $400 million, according to reports

Note: The $90 million figure relates to reported negotiations, not a completed transaction. The funding total represents capital raised over the company’s history and is not the same as its current cash balance or enterprise value.

A large valuation decline does not necessarily mean that the business has lost the same amount of cash. Startup valuations reflect investor expectations about future growth, profitability, competitive position and the likelihood of generating returns.

When those expectations change, a company’s valuation can fall substantially even if it still holds cash or owns operational assets.

DealShare’s reported situation illustrates the difference between a company’s historical fundraising valuation and what a potential buyer may be willing to pay under current circumstances.

How DealShare’s Business Model Changed

DealShare built its business around affordable online shopping, with a focus on groceries and everyday household products for consumers in India’s tier-II and tier-III cities.

Its proposition centred on value: helping customers purchase essential goods at competitive prices through a digital platform. The company attracted investors by targeting a large market of consumers who were increasingly adopting online shopping but remained sensitive to prices.

However, competition in Indian e-commerce intensified. Grocery delivery businesses faced pressure to offer convenience, competitive pricing and faster fulfilment while controlling warehousing, delivery, customer acquisition and other operating expenses.

DealShare attempted to adjust its strategy by moving towards a revised business model that combined value commerce with faster delivery and physical retail.

The shift towards faster delivery

DealShare’s revised approach included a two-hour delivery model intended to combine affordability with convenience. But operating an online grocery business requires more than demand for inexpensive products.

Companies must manage inventory, fulfilment facilities, delivery networks and order economics. Faster delivery can improve customer experience, but it can also increase operating complexity and costs if order volumes and average basket sizes are insufficient.

According to Inc42’s September reporting, DealShare began scaling back its online operations around April 2026 and eventually stopped fulfilling orders from its warehouses. Its online business was reported to have dwindled to a negligible level.

Physical stores become more important

DealShare subsequently leaned more heavily on its physical retail presence. The stores provided a different way to reach consumers, but they also required a clear strategy for locations, inventory, store-level profitability and expansion.

Inc42 reported in September that approximately 22 stores remained operational, while plans for further expansion had been put on hold.

The transition raises a fundamental question: should DealShare operate primarily as a physical retailer, an online marketplace or an integrated business combining both?

Each model has different capital requirements and operating economics. An omnichannel strategy can create advantages if stores support online fulfilment and customer acquisition, but it also requires coordination between digital systems, inventory and physical operations.

DealShare’s difficulty in establishing a consistent direction has become an important part of the uncertainty surrounding its future.

Founder Departures and Management Turnover

DealShare’s leadership changes extend beyond Singh’s departure.

The company experienced several founder exits during its restructuring period. Its leadership transition included the departures of co-founders Vineet Rao, Sankar Bora and Sourjyendu Medda, while Rajat Shikhar also left the company, according to startup-industry reporting.

Singh’s appointment as CEO in January 2024 was part of an effort to stabilise the business and improve its operating model. His exit now creates another transition at a time when the company’s future ownership remains unresolved.

Inc42 also reported that CFO Ashish Shah was looking to leave the company. This was a reported development rather than confirmation of a completed departure.

Management turnover matters because acquisition negotiations require financial reporting, operational planning, employee communication and decisions about what the business should look like under new ownership.

A potential buyer may also need clarity on leadership responsibilities, ongoing liabilities, employee retention, store operations and technology infrastructure before completing a transaction.

The reported departures do not establish that a sale will fail. They do, however, underline the importance of continuity and clear decision-making while the company evaluates its options.

What Could Truemeds Gain From DealShare?

Truemeds operates in a different category from DealShare. It focuses on online pharmacy and medicine purchases, whereas DealShare’s original proposition centred on affordable groceries and household essentials.

An acquisition would therefore not be a straightforward combination of two identical businesses. Its strategic value would depend on what Truemeds intended to acquire and how the assets would support its own plans.

Potential areas of interest could include DealShare’s remaining financial resources, corporate infrastructure, retail assets or other capabilities. However, the precise rationale for the proposed transaction has not been conclusively established in the available reporting.

If the transaction proceeds as a share swap, the resulting ownership structure and the value assigned to each company’s shares would be important considerations. Existing investors in both businesses would need to assess whether the arrangement serves their interests.

The reported concerns among Truemeds investors illustrate a central challenge in startup acquisitions: a transaction can appear attractive to some stakeholders while raising questions for others.

Without a definitive agreement and official disclosures, it would be premature to conclude that the deal will deliver specific synergies, improve profitability or guarantee DealShare’s continued operations.

What Happens if the Acquisition Does Not Go Through?

If Truemeds does not acquire DealShare, the company may need to continue exploring alternative buyers or determine whether its remaining operations can function as a standalone business.

Its options could depend on its available cash, ongoing expenses, retail performance, contractual obligations and investor willingness to provide additional support. A business with a smaller operating footprint may be able to reduce costs, but it still needs a viable plan for generating revenue and meeting its obligations.

Earlier reporting has suggested that DealShare was evaluating other potential buyers. That means a failed transaction with Truemeds would not automatically establish that the company would shut down.

At the same time, a prolonged sale process could make business planning more difficult. Employees, suppliers, landlords and other partners may seek clarity about future operations, payments and management responsibilities.

The outcome will depend on negotiations and the company’s financial and operational position. No definitive conclusion about a sale, shutdown or continuation should be drawn until the relevant parties provide confirmation.

The Bigger Picture

DealShare’s situation highlights the challenges facing e-commerce startups that build their businesses around affordability while competing in a market where delivery speed, fulfilment costs and customer retention are increasingly important. A strong fundraising history and a high peak valuation do not guarantee that a business model will remain sustainable as competition and operating conditions change.

The reported Truemeds discussions also demonstrate how startup acquisitions can become a route to restructuring when a company’s original growth strategy loses momentum. For DealShare, the next phase will depend on whether a buyer and its investors can agree on a transaction, or whether the company can establish a credible standalone strategy.

Looking Ahead

The immediate developments to watch are the appointment of DealShare’s next CEO, any official announcement about the Truemeds negotiations and further clarity on the company’s operating footprint. Confirmation of a definitive agreement would be necessary to establish the final transaction structure, valuation and treatment of existing shareholders.

Until then, the reported $90 million valuation should be treated as indicative rather than final. DealShare’s future will depend on the outcome of negotiations, the resources available to sustain its remaining business and the ability of its stakeholders to agree on a workable path forward.

Frequently Asked Questions

1. Why did DealShare CEO Kamaldeep Singh quit?

Reports published on October 13, 2026, said Singh stepped down and moved to Indofast Energy as CEO. The available reporting does not establish that the reported acquisition discussions caused his departure.

2. Is Truemeds acquiring DealShare?

DealShare has reportedly held advanced discussions with Truemeds about a potential acquisition through a share-swap transaction. As of October 13, 2026, the available reporting does not confirm that the deal has been completed.

3. What is DealShare’s reported valuation in the potential deal?

Reports have placed the potential valuation at just over $90 million, compared with DealShare’s peak valuation of approximately $1.7 billion in 2022. The proposed valuation is not a confirmed final sale price.

4. Why has DealShare struggled?

DealShare has faced competitive pressure and challenges in building a sustainable online grocery and rapid-delivery model. It has scaled back online fulfilment and shifted attention towards physical stores while evaluating its future business strategy.

5. Who is Kamaldeep Singh joining after leaving DealShare?

Singh is moving to Indofast Energy as its CEO. The company operates in the electric mobility sector, including battery-swapping and battery-as-a-service solutions.

6. What happens if the Truemeds deal fails?

DealShare could continue discussions with other potential buyers or consider alternatives for its remaining operations. The outcome is uncertain, and no final decision should be assumed without further confirmation.